GENPREX (NASDAQ:GNPX) Raised to Sell at Wall Street Zen

GENPREX (NASDAQ:GNPX) was upgraded by investment analysts at Wall Street Zen to a “sell” rating in a report released on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of GENPREX in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

GENPREX Trading Down 23.7%

GENPREX stock opened at $0.36 on Friday. The business’s 50-day simple moving average is $0.23 and its 200 day simple moving average is $0.26. GENPREX has a 12-month low of $0.14 and a 12-month high of $3.97.

GENPREX (NASDAQ:GNPX) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.54. Equities research analysts forecast that GENPREX will post -5.7 EPS for the current fiscal year.

About GENPREX

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.